Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Stock Information for Bright Minds Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Bright Minds Biosciences Inc.

Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting
Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)
Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH
Bright Minds Biosciences to Present at Upcoming Conferences
BRIGHT MINDS BIOSCIENCES ANNOUNCES AT-THE-MARKET OFFERING
Bright Minds Biosciences Announces BMB?201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
Bright Minds Biosciences to Present at Upcoming Conferences
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.